A Research on Formulation and Evaluation of Celecoxib Fast Disintegrating Capsule (200mg)

Fast-disintegrating capsules have gained significant interest due to their potential to enhance patient compliance and drug efficacy. Celecoxib, a non-steroidal anti-inflammatory drug (NSAID), known for its selective inhibition of cyclooxygenase-2 (COX-2), is commonly used for the management of pain and inflammation associated with arthritis and other conditions. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits cyclooxygenase- 2 (COX-2),enzyme involved in the synthesis of prostaglandins. Prostaglandins play a key role in inflammation, pain perception, and fever response. By selectively inhibiting COX-2, celecoxib reduces the production of prostaglandins that promote inflammation and pain, while sparing COX-1 activity to a greater extent. This study aimed to develop and evaluate a fast-disintegrating capsule formulation of Celecoxib to provide rapid onset of action and improved patient convenience. The formulation was optimized using a combination of superdisintegrants and excipients to achieve fast disintegration in oral cavity conditions. Physicochemical characterization including disintegration time,and drug content uniformity were evaluated. In vitro dissolution studies were conducted to assess drug release profiles. The optimized formulation demonstrated rapid disintegration within seconds and showed comparable dissolution profiles to commercially available Celecoxib capsules. Further studies are warranted to evaluate the pharmacokinetic and pharmacodynamic profiles of the fast-disintegrating Celecoxib capsule in clinical settings to validate its potential therapeutic benefits.

• Publication year

  2025

• Venue

  International Journal For Multidisciplinary Research

• Publication date

  2025-07-09

• Fields of study

  Not labeled

• Identifiers
  DOI 10.36948/ijfmr.2025.v07i04.50606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Celecoxib for rheumatoid arthritis.

  2017cited by this paper
• Celecoxib pathways: pharmacokinetics and pharmacodynamics.

  2012cited by this paper
• Celecoxib, NSAIDs and the skeleton.

  2008cited by this paper
• Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

  1999cited by this paper
• Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

  1997cited by this paper
• Eicosanoids and the gastrointestinal tract.

  1995cited by this paper
• Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

  1993cited by this paper
• Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.

  1992cited by this paper
• Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide.

  1992cited by this paper
• A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein.

  1991cited by this paper
• Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.

  1991cited by this paper
• Acetylation of prostaglandin synthetase by aspirin. Purification and properties of the acetylated protein from sheep vesicular gland.

  1977cited by this paper

• No citing papers are available for this paper.